FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to chemical-pharmaceutical industry and can be applied for treatment of type 2 diabetes mellitus. Composition containa as active substances N-(β-oxyethyl)-4,6-dimethyldihydropyrimedone-2 (xymedon) and inulin in ratio (2.5-5):(1-3). Composition can additionally contain magnesium, zinc, chromium asparaginates and can be made in form of capsules or pills.
EFFECT: effect from application of pharmaceutical composition for treatment of type 2 diabetes mellitus consists in continuous reduction of glucose level in blood and normalisation of lipid metabolism parameters.
13 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION POSSESSING ANTIDIABETIC, HYPOLIPIDEMIC, HYPOGLYCEMIC AND CHOLESTEROL LOWERING ACTION, WAY OF ITS RECEPTION AND WAYS OF TREATMENT OF SPECIFIED DISEASES | 2007 |
|
RU2361581C2 |
| METHOD FOR COMBINED USE OF INTRANASALLY ADMINISTERED INSULIN AND ORALLY ADMINISTERED METFORMIN FOR RECOVERY OF METABOLIC AND HORMONAL PARAMETERS IN TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME | 2023 |
|
RU2824275C1 |
| SOLIDPHASE COMPOSITION OF NATURAL BIOACTIVE INGREDIENTS FOR CORRECTION OF METABOLIC DISTURBANCES IN DIABETES MELLITUS TYPE II | 2017 |
|
RU2661622C1 |
| COMBINATION FOR TREATMENT OF DIABETES AND COMPLICATIONS THEREOF | 2011 |
|
RU2451506C1 |
| AGENT FOR PREVENTING AND TREATING INSULIN-INDEPENDENT DIABETES | 2011 |
|
RU2458701C1 |
| METHOD OF TREATING DIABETES MELLITUS AND COMBINED MEDICATION | 2013 |
|
RU2565401C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND FIBRATE IN COMBINATION AND ITS USING IN PREPARING MEDICINAL AGENTS DESIGNATED FOR HYPERGLYCEMIA REDUCTION | 1999 |
|
RU2207850C2 |
| AGENT FOR TREATING DIABETES, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISEASES | 2011 |
|
RU2482868C1 |
| NOVEL VANADIUM DERIVATIVES HAVING HYPOGLYCEMIC ACTIVITY | 2019 |
|
RU2709491C1 |
| SOLID-PHASE COMPOSITION FOR CORRECTION OF METABOLIC DISORDERS IN TYPE 2 DIABETES MELLITUS | 2020 |
|
RU2747985C1 |
